Gan & Lee Pharmaceuticals' (SHA:603087) Shandong subsidiary received clinical trial approval from China's National Medical Products Administration for its investigational GZC8072 drug for weight control, according to a Tuesday filing with the Shanghai bourse.
The tablets use the company's peptide technology platforms for a once-weekly regimen, the diabetes drug maker said.